戻る Agenda
[V1-S3] What is the Goal of Patient-Engaged Drug Development?
Session Chair(s)
Kaori Muto, PHD
Professor, Department of Public Policy, The Institute of Medical Science
The University of Tokyo, Japan
The idea that medical treatment and drug development is something only for doctors and pharmaceutical companies is becoming a thing of the past. While many people have been working on realizing drug development that meets real patients’ needs through this enhanced, patient-engaged approach, concerns remain about whether the challenges of this goal are properly aligned among stakeholders. This session will discuss the goal of patient-engaged drug development with panelists from patient, academia, and industry sides, including what is needed to create greater value for patients as well as for those stakeholders who support the patient-engaged approach.
Speaker(s)
Industry’s Perspective on “Patient Engagement”
Satoshi Miki
UCB Japan Co., Ltd., Japan
Senior Advisor
"Patient Engagement" from the Ethics Point of View
Haruka Nakada, JD, PHD
The Institute of Medical Science, The University of Tokyo, Japan
Project Research Fellow, Department of Public Policy, Human Genome Center
Patient’s Perspective on “Patient Engagement”
Ikuko Yamaguchi
NPO COML, Japan
Board Chairperson